Tm-Values and Unfolded Fraction Can Predict Aggregation Rates for Granulocyte Colony Stimulating Factor Variant Formulations but Not under Predominantly Native Conditions.

Protein engineering and formulation optimization strategies can be taken to minimize protein aggregation in the biopharmaceutical industry. Short-term stability measures such as the midpoint transition temperature (Tm) for global unfolding provide convenient surrogates for longer-term (e.g., 2-year) degradation kinetics, with which to optimize formulations on practical time-scales. While successful in some cases, their limitations have not been fully evaluated or understood. Tm values are known to correlate with chemical degradation kinetics for wild-type granulocyte colony stimulating factor (GCSF) at pH 4-5.5. However, we found previously that the Tm of an antibody Fab fragment only correlated with its rate of monomer loss at temperatures close to the Tm. Here we evaluated Tm, the fraction of unfolded protein (fT) at temperature T, and two additional short-term stability measures, for their ability to predict the kinetics of monomer and bioactivity loss of wild-type GCSF and four variants, at 37 °C, and in a wide range of formulations. The GCSF variants introduced one to three mutations, giving a range of conformational stabilities spanning 7.8 kcal mol-1. We determined the extent to which the formulation rank order differs across the variants when evaluated by each of the four short-term stability measures. All correlations decreased as the difference in average Tm between each pair of GCSF variants increased. The rank order of formulations determined by Tm was the best preserved, with R2-values >0.7. Tm-values also provided a good predictor (R2 = 0.73) of the aggregation rates, extending previous findings to include GCSF variant-formulation combinations. Further analysis revealed that GCSF aggregation rates at 37 °C were dependent on the fraction unfolded at 37 °C (fT37), but transitioned smoothly to a constant baseline rate of aggregation at fT37 < 10-3. A similar function was observed previously for A33 Fab formulated by pH, ionic strength, and temperature, without excipients. For GCSF, all combinations of variants and formulations fit onto a single curve, suggesting that even single mutations destabilized by up to 4.8 kcal mol-1, are insufficient to change significantly the baseline rate of aggregation under native conditions. The baseline rate of aggregation for GCSF under native conditions was 66-fold higher than that for A33 Fab, highlighting that they are a specific feature of each native protein structure, likely to be dependent on local surface properties and dynamics.

[1]  C. Kolvenbach,et al.  Granulocyte‐colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH 2 , 2009 .

[2]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[3]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[4]  S. Radford,et al.  Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. , 2005, Journal of molecular biology.

[5]  Bradford Stanley,et al.  Control of Protein Particle Formation During Ultrafiltration/Diafiltration Through Interfacial Protection , 2014, Journal of pharmaceutical sciences.

[6]  Massimo Morbidelli,et al.  Population balance modeling of antibodies aggregation kinetics. , 2012, The journal of physical chemistry. B.

[7]  Naresh Chennamsetty,et al.  Predictive tools for stabilization of therapeutic proteins , 2009, mAbs.

[8]  J. Straub,et al.  Propensity to form amyloid fibrils is encoded as excitations in the free energy landscape of monomeric proteins. , 2014, Journal of molecular biology.

[9]  Ashley C. Gucinski,et al.  Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers , 2014, Analytical and Bioanalytical Chemistry.

[10]  Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor , 2012, Biotechnology Letters.

[11]  J. Cayuela,et al.  Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements , 2007, Leukemia.

[12]  W. Jiskoot,et al.  Aggregation and Immunogenicity of Therapeutic Proteins , 2010 .

[13]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[14]  Michael J. Pikal,et al.  Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice , 1997, Pharmaceutical Research.

[15]  Andreas Zimmer,et al.  Evaluating the effects of buffer conditions and extremolytes on thermostability of granulocyte colony-stimulating factor using high-throughput screening combined with design of experiments. , 2012, International journal of pharmaceutics.

[16]  D Eisenberg,et al.  The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Xuejun Han,et al.  Protein aggregation kinetics during Protein A chromatography. Case study for an Fc fusion protein. , 2007, Journal of chromatography. A.

[18]  Paul A Dalby,et al.  Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment. , 2016, Molecular pharmaceutics.

[19]  Theodore W Randolph,et al.  Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. , 2002, Biochemistry.

[20]  T. Boone,et al.  Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. , 1996, Pharmaceutical biotechnology.

[21]  L. Regan,et al.  Reengineering Granulocyte Colony-stimulating Factor for Enhanced Stability* , 2001, The Journal of Biological Chemistry.

[22]  R. Tierney,et al.  Optimization of the formulation for a candidate lyophilised tetanus toxoid reference preparation. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[23]  C. Dobson Protein folding and misfolding , 2003, Nature.

[24]  Theodore W Randolph,et al.  Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony‐stimulating factor , 2003, Protein science : a publication of the Protein Society.

[25]  A. Hubbard,et al.  Impact of residual moisture and formulation on Factor VIII and Factor V recovery in lyophilized plasma reference materials , 2007, Analytical and bioanalytical chemistry.

[26]  S. Vignesh,et al.  Mutational Analysis on Human Granulocyte Macrophage-Colony Stimulating Factor Stability Using Computational Approaches , 2015 .

[27]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[28]  Paul Matejtschuk,et al.  A comparison of vials with ampoules for the storage of biological reference materials. , 2005, Biologicals : journal of the International Association of Biological Standardization.

[29]  D. Lauffenburger,et al.  Parsing the Effects of Binding, Signaling, and Trafficking on the Mitogenic Potencies of Granulocyte Colony‐Stimulating Factor Analogues , 2003, Biotechnology progress.

[30]  J. King,et al.  Aggregation of granulocyte‐colony stimulating factor in vitro involves a conformationally altered monomeric state , 2005, Protein science : a publication of the Protein Society.

[31]  Vidyashankara G. Iyer,et al.  High throughput prediction of the long-term stability of pharmaceutical macromolecules from short-term multi-instrument spectroscopic data. , 2014, Journal of pharmaceutical sciences.

[32]  A. Fersht,et al.  Conformational entropy of alanine versus glycine in protein denatured states , 2007, Proceedings of the National Academy of Sciences.

[33]  Anirban Kundu,et al.  Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening , 2002, Protein science : a publication of the Protein Society.